Free Shipping in the U.S. for orders over $1000.  Shop Now>>

Recombinant Plasminogen Activator Inhibitor (Type 1) / PAI-1 (Breast Cancer Prognostic Marker) Antibody [rTJA6]

In Stock
Catalog Number Formulation Size Price
5054-MSM3-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$249.00
5054-MSM3-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$539.00
5054-MSM3-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$539.00
Flat Rate Domestic: $75 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes
Western Blot (WB)
2-4ug/ml

Summary

This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. The protein also functions as a component of innate antiviral immunity. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia.

Product Properties & Targets

Host
Mouse
Species Reactivity
Research Areas
Isotype / Light Chain
IgG2b / Kappa
Cellular Localization
Secreted
Gene Name
Positive Control
A-431 cells. Human placenta, lung or breast cancer.
Immunogen
Prokaryotic recombinant protein corresponding to a 250 amino acid portion of the N-terminus of the human PAI-1 molecule
Alternate Names
plasminogen activator inhibitor 1, PAI; PAI1; PAI-1; PLANH1, endothelial plasminogen activator inhibitor serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 serpin E1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
rTJA6
Chromosome Location
7q22.1
Mol. Weight of Antigen
50kDa

Functions

  • Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:17912461, PubMed:8481516, PubMed:9207454). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084).

Key References

  • Thanakit V, Sampatanukul P, Ruangvejvorachai P, Keelawat S. J Med Assoc Thai. 2005 Sep;88 Suppl 4:S30-5.
  • Elsasser, A., et al. 2004. J. Am. Coll. Cardiol. 43: 2191-2199.
  • Dublin E, Hanby A, Patel N K, et al. American Journal of Pathology. 157 (4): 1219–1227 (2000).
  • de Witte J H, Sweep C G, Klijn J G, et al. British Journal of Cancer. 80 (1–2): 286–294 (1999).
  • Hartbeck N, Thomssen C, Berger U, et al. Breast Cancer Research Treatment. 54 (2): 147–157 (1999).
  • Arai Y, Kubota T, Nakagawa T, et al. Acta. Neurochir. (Wien). 140 (4): 377–385 (1998).
  • Strojan P, Budihna M, Smid L, et al. European Journal of Cancer. 34 (8): 1193–1197 (1998).
  • Sweep C G, Geurts-Moespot J, Grebenschikov N, et al. British Journal of Cancer. 78 (11): 1434–1441 (1998).
  • Speiser P, Mayerhofer K, Kucera E, et al. Anticancer Research. 17 (1B): 679–683 (1997).
  • Ito H, Yonemura Y, Fujita H, et al. Virchows Arch. 427 (5): 487–496 (1996).
  • Zellinger R, Eder S, Schneeberger C, et al. Anticancer Research. 16 (1): 449–453 (1996).
  • Sancho E, Declerck P J, Price N C, et al. Biochemistry. 34 (3): 1064–1069 (1995).
  • Keijer J, Linders M, van Zonneveld A-J, et al. Blood. 78 (2): 401–409 (1991).
  • Munch M, Heegaard C, Jensen P H, et al. FEBS. 295 (1,2,3): 102–106 (1991).

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab produced in CHO cell mammalian-based expression system. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant Plasminogen Activator Inhibitor (Type 1) / PAI-1 (Breast Cancer Prognostic Marker) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK